News & Updates
Filter by Specialty:
Pembrolizumab improves DFS in completely resected stage IB–IIIA NSCLC
Adjuvant pembrolizumab significantly improves disease-free survival (DFS) vs placebo in patients with completely resected, PD-L1–unselected, stage IB–IIIA non-small-cell lung cancer (NSCLC), a second interim analysis of the triple-blind phase III PEARLS/KEYNOTE-091 trial has shown.
Pembrolizumab improves DFS in completely resected stage IB–IIIA NSCLC
20 Oct 2022
High egg intake poses no risk of cardiovascular events
People who like eating eggs do not seem to be at higher risk of myocardial infarction (MI), ischaemic coronary heart disease (ICHD), stroke, and cardiovascular disease (CVD), suggests the results of a recent study in Iran.
High egg intake poses no risk of cardiovascular events
19 Oct 2022
Metformin plus R-form verapamil improves glycaemic control in T2D
Combination therapy with metformin plus R-form verapamil (R-Vera) leads to significant improvements in glycaemic control by reducing haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) among patients with type 2 diabetes (T2D), reports a study.
Metformin plus R-form verapamil improves glycaemic control in T2D
19 Oct 2022
Liver enzymes mediate association of particulate matter exposure with diabetes risk
Liver enzymes play a partial role in the relationship between exposure to particulate matter (PM) and risk of diabetes, indicating the involvement of lipid accumulation, oxidative stress, and chronic inflammation in the liver in its pathogenesis, reports a recent study.
Liver enzymes mediate association of particulate matter exposure with diabetes risk
19 Oct 2022
Lenvatinib-pembrolizumab combo fails to spring forward in HCC treatment
In the phase III LEAP*-002 study, a combination regimen comprising lenvatinib and pembrolizumab appeared to have similar efficacy and safety as lenvatinib monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC).
